Pancreatic Cancer Research

ResearcherShizuoka Cancer CenterActive in the last 2 years

Teiichi Sugiura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7163-4084; OpenAlex author ID A5053487834, A5108728143. Sources: OpenAlex.

Their work

Papers
60 (first author 11, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
115
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: none · 2017: 4 papers · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 9 papers · 2022: 7 papers · 2023: 9 papers · 2024: 2 papers · 2025: 5 papers · 2026: 12 papers

Papers 50 of 60

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  3. Outcomes of conversion surgery for patients with locally advanced pancreatic cancer under strict indication criteria. Last author DOI 10.1007/s00595-025-03223-7↗
  4. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  5. Intraoperative decision-making for pancreatic ductal adenocarcinoma with occult para-aortic lymph node metastasis: Proposal of a pathology-based weighted risk … First author DOI 10.1016/j.suronc.2026.102559↗
  6. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… Co-author DOI 10.1097/sla.0000000000007012↗
  7. Impact of CYP2A6 Genotype on Survival Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Receiving Perioperative S-1 Therapy. Last author DOI 10.1097/sla.0000000000007152↗
  8. Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features. Last author DOI 10.1245/s10434-025-18556-3↗
  9. ASO Author Reflections: Genomic Features of Familial and Sporadic Pancreatic Cancer. Last author DOI 10.1245/s10434-025-18624-8↗
  10. Prognostic Significance of Radiological Adjacent Organ Invasion in Resectable Left-Sided Pancreatic Cancer. Last author DOI 10.1245/s10434-026-19244-6↗
  11. ASO Author Reflections: Rethinking Resectability in Left-Sided Pancreatic Cancer-The Clinical Meaning of Radiological Adjacent Organ Invasion. Last author DOI 10.1245/s10434-026-19394-7↗
  12. ASO Visual Abstract: Prognostic Significance of Radiological Adjacent Organ Invasion in Resectable Left-Sided Pancreatic Cancer. Last author DOI 10.1245/s10434-026-19416-4↗
  13. Association Between the Degree of Arterial Contact Angle and Survival in Patients With Borderline Resectable Pancreatic Cancer. Last author DOI 10.1002/ags3.70052↗
  14. Clinical significance of resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma with occult para-aortic lymph node metastasis. Last author DOI 10.1016/j.surg.2024.10.016↗
  15. Impact of Perioperative Hemoglobin A1c Levels on Survival Outcomes of Patients With Pancreatic Cancer: A Retrospective Study. Last author DOI 10.1097/as9.0000000000000597↗
  16. Efficacy of Neoadjuvant Therapy for Resectable Pancreatic Cancer Might be Limited to Biologically Borderline Resectable Cases. Last author DOI 10.1097/mpa.0000000000002485↗
  17. Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18084-0↗
  18. Predictive factors of actual 5-y recurrence-free survival after upfront surgery for resectable pancreatic cancer: Exploration of patients who did not require n… First author DOI 10.1002/ags3.12834↗
  19. Comprehensive sequencing of circulating tumour DNA in resectable pancreatic cancer. Co-author DOI 10.1093/bjs/znae059↗
  20. Genomic landscape of pancreatic cancer in the Japanese version of the Cancer Genome Atlas. Co-author DOI 10.1002/ags3.12636↗
  21. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  22. Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancre… Co-author DOI 10.1002/jhbp.1353↗
  23. Long-term adjuvant chemotherapy after resection for pancreatic cancer patients with positive peritoneal lavage cytology. First author DOI 10.1007/s00423-023-02906-4↗
  24. Corrigendum to Clinical significance of immunocytochemical staining for peritoneal lavage cytology in pancreatic cancer: [Surgery. 2022;172(6):1776-81, DOI: 10… Co-author DOI 10.1016/j.surg.2023.05.001↗
  25. Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients. Co-author DOI 10.1038/s10038-022-01097-y↗
  26. Characterization of pancreatic cancer with ultra-low tumor mutational burden. Co-author DOI 10.1038/s41598-023-31579-8↗
  27. Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Levels in Patients with Pancreatic Cancer. First author DOI 10.1245/s10434-023-13564-7↗
  28. ASO Author Reflections: Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Values in Patients with Pancreatic Cancer: Focusing on the Us… First author DOI 10.1245/s10434-023-13629-7↗
  29. The prognostic impact of ABO blood type in pancreatic cancer: Relevance to adjuvant chemotherapy. Co-author DOI 10.1002/jhbp.1152↗
  30. The clinical benefits of performing staging laparoscopy for pancreatic cancer treatment. Co-author DOI 10.1016/j.pan.2022.03.017↗
  31. Clinical significance of immunocytochemical staining for peritoneal lavage cytology in pancreatic cancer. Co-author DOI 10.1016/j.surg.2022.09.025↗
  32. Resectability Status of Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery: Is Upfront Surgery Justified? Co-author DOI 10.1245/s10434-022-11624-y↗
  33. The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Ven… Co-author DOI 10.1245/s10434-022-11628-8↗
  34. ASO Author Reflections: Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery Should be Regarded as Technically Resectable but Oncologic… Co-author DOI 10.1245/s10434-022-11639-5↗
  35. ASO Author Reflections: Neoadjuvant Therapy for Pancreatic Cancer may Reduce Microscopic Venous Invasion, Which is an Independent Prognostic Factor Associated … Co-author DOI 10.1245/s10434-022-11662-6↗
  36. The influence of familial pancreatic cancer on postoperative outcome in pancreatic cancer: relevance to adjuvant chemotherapy. Co-author DOI 10.1007/s00535-020-01730-7↗
  37. The preoperative controlling nutritional status (CONUT) score is an independent prognostic marker for pancreatic ductal adenocarcinoma. First author DOI 10.1007/s13304-020-00792-9↗
  38. Comparison of five-phase computed tomography images of type 1 autoimmune pancreatitis and pancreatic cancer: Emphasis on cases with atypical images. Co-author DOI 10.1016/j.pan.2021.01.016↗
  39. Predictive factors of survival in patients with borderline resectable pancreatic cancer who received neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2021.08.009↗
  40. Histological Differentiation Is a Pivotal Prognostic Factor Associated With the Pattern of Recurrence Following Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001848↗
  41. Reconsidering the Optimal Regional Lymph Node Station According to Tumor Location for Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09066-5↗
  42. Clinical Implication of Node-negative Resectable Pancreatic Cancer. First author DOI 10.1245/s10434-020-09543-x↗
  43. Clinical Significance of Preoperative Albumin-Bilirubin Grade in Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-09593-9↗
  44. ASO Author Reflections: Albumin-Bilirubin Grade is an Independent Prognostic Factor Complementary to CA19-9 for Pancreatic Cancer Patients. Co-author DOI 10.1245/s10434-021-09660-1↗
  45. Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus. First author DOI 10.1007/s00423-020-01874-3↗
  46. Prognostic impact of abutment to the branches of the superior mesenteric artery in borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00423-020-01970-4↗
  47. Middle segment-preserving pancreatectomy for multifocal pancreatic ductal adenocarcinoma located in the head and tail of the pancreas: a case report. Co-author DOI 10.1093/jscr/rjaa383↗
  48. Prognostic role of the length of tumour-vein contact at the portal-superior mesenteric vein in patients having surgery for pancreatic cancer. Co-author DOI 10.1002/bjs.11328↗
  49. A case of pancreatic cancer invading the superior mesenteric artery causing extensive intestinal necrosis that was successfully treated by surgery. Co-author DOI 10.1093/jscr/rjz118↗
  50. Microscopic Venous Invasion in Pancreatic Cancer. First author DOI 10.1245/s10434-017-6324-2↗

Closest collaborators

The 25 strongest of 115 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Katsuhisa Ohgi · 43 shared papers, 2019–2026 · strength 7.94
  2. Katsuhiko Uesaka · 50 shared papers, 2011–2026 · strength 7.85
  3. Ryo Ashida · 42 shared papers, 2017–2026 · strength 7.38
  4. Yukiyasu Okamura · 29 shared papers, 2011–2026 · strength 3.84
  5. Mihoko Yamada · 18 shared papers, 2018–2026 · strength 3.37
  6. Yoshiyasu Kato · 10 shared papers, 2025–2026 · strength 2.74
  7. Takaaki Ito · 16 shared papers, 2017–2022 · strength 1.83
  8. Taisuke Imamura · 10 shared papers, 2019–2024 · strength 1.40
  9. Keiichi Ohshima · 6 shared papers, 2023–2026 · strength 1.36
  10. Satoshi Hirano · 6 shared papers, 2023–2026 · strength 1.17
  11. Akiko Todaka · 9 shared papers, 2017–2023 · strength 1.16
  12. Takumi Kitahama · 4 shared papers, 2026 · strength 1.14
  13. Yuya Miura · 5 shared papers, 2022–2026 · strength 1.14
  14. Kentaro Yamazaki · 6 shared papers, 2017–2025 · strength 1.03
  15. Sohei Satoi · 5 shared papers, 2023–2026 · strength 0.98
  16. Hidemasa Kubo · 5 shared papers, 2022–2025 · strength 0.87
  17. Kenichi Urakami · 4 shared papers, 2023–2026 · strength 0.83
  18. Kenichiro Uemura · 4 shared papers, 2025–2026 · strength 0.83
  19. Michiaki Unno · 4 shared papers, 2023–2026 · strength 0.76
  20. So Yamaki · 3 shared papers, 2025–2026 · strength 0.60
  21. Kenjiro Okada · 3 shared papers, 2025–2026 · strength 0.60
  22. Masamichi Mizuma · 3 shared papers, 2025–2026 · strength 0.60
  23. Atsushi Oba · 3 shared papers, 2025–2026 · strength 0.60
  24. Daisuke Hashimoto · 3 shared papers, 2025–2026 · strength 0.60
  25. Koetsu Inoue · 3 shared papers, 2025–2026 · strength 0.60

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.